Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HCC1806 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 7830.018 | uM | inf | inf | 0.8437 | 0.8437 | 0.0000 | -0.0352 | 0.4991 | 1.5320 | |
HCC1806 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 9376.026 | uM | inf | 0.00355 | 0.6382 | 0.6973 | 1.1036 | 0.0999 | 0.9151 | 1.6827 | |
HCC1806 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 7829.042 | uM | inf | 0.00429 | 0.6767 | 0.7343 | 5.0000 | 0.1048 | 0.9467 | 1.8673 | |
MCF 10F | NM | - | Trastuzumab | HER2 | ErbB | 7487.102 | uM | 5.78510 | 28.60730 | 0.4084 | -1.0000 | 0.6873 | 0.0988 | 0.8554 | 1.5273 | |
SUM185PE | TNBC | Luminal | Cetuximab | EGFR | ErbB | 7921.042 | uM | inf | inf | 1.0399 | 1.0399 | 0.0000 | -0.0494 | -236.5755 | 0.6355 | |
SUM185PE | TNBC | Luminal | Cetuximab | EGFR | ErbB | 10146.124 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.9296 | |
HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 9501.026 | uM | inf | 0.01283 | 0.4925 | 0.5840 | 1.2619 | 0.0978 | 0.8957 | 0.7616 | |
MCF7 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 7874.018 | uM | inf | inf | 0.9611 | 0.9611 | 0.0000 | -0.0261 | -0.1994 | 1.6506 | |
MCF 10A | NM | Basal B | Trastuzumab | HER2 | ErbB | 9551.026 | uM | inf | inf | 0.9124 | 0.9124 | 0.0000 | -0.0111 | 0.4645 | 2.6508 | |
MCF7 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 7875.018 | uM | inf | inf | 0.9316 | 0.9316 | 0.0000 | -0.0136 | 0.3967 | 1.6565 | |
MDA-MB-436 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 7902.018 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0247 | -0.1948 | 1.8686 | |
MCF 10F | NM | - | Cetuximab | EGFR | ErbB | 7871.018 | uM | inf | inf | 0.9011 | 0.9011 | 0.0000 | -0.0407 | -0.0154 | 1.1973 | |
MDA-MB-436 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 7898.018 | uM | inf | inf | 0.9583 | 0.9583 | 0.0000 | -0.0243 | -0.0431 | 1.1279 | |
MDA-MB-436 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 7900.018 | uM | inf | inf | 0.5694 | 0.5694 | 0.0000 | 0.2033 | -0.0548 | 0.8304 | |
MCF 10A | NM | Basal B | Cetuximab | EGFR | ErbB | 7867.042 | uM | 0.82087 | 0.24212 | 0.5210 | 0.3793 | 1.1638 | 0.0459 | 0.9580 | 2.3427 | |
HCC1806 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 9376.026 | uM | inf | inf | 0.9395 | 0.9395 | 0.0000 | -0.0232 | 0.0979 | 1.6827 | |
MDA-MB-175-VII | HR+ | Luminal | Cetuximab | EGFR | ErbB | 7884.018 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.6074 | |
SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 7920.018 | uM | inf | inf | 0.9492 | 0.9492 | 0.0000 | 0.0108 | 0.4781 | 4.3723 | |
HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 10268.122 | uM | 0.92849 | 0.80222 | 0.7620 | 0.2528 | 4.8199 | -0.0144 | 0.6866 | 0.6345 | |
MDA-MB-436 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 7899.018 | uM | inf | inf | 0.8519 | 0.8519 | 0.0000 | 0.0052 | 0.3918 | 2.0432 | |
HBL-100 | Unknown | Unknown | Pertuzumab | 7429.102 | mg/ml | inf | 0.21142 | 0.9391 | 0.9176 | 0.6095 | 0.0085 | 0.7039 | 2.4347 | |||
HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 7860.042 | uM | 1.41750 | 6.04060 | 0.6742 | -0.9996 | 0.7577 | 0.0164 | 0.8799 | 0.6736 | |
HCC1937 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 7832.042 | uM | 0.57736 | 1.87360 | 0.4323 | -1.0000 | 0.9333 | 0.0778 | 0.8653 | 1.2810 | |
LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 7865.018 | uM | inf | inf | -0.1870 | -0.1870 | 0.0000 | 0.5240 | -0.0010 | 1.1920 | |
LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 9536.006 | uM | inf | inf | 0.9716 | 0.9716 | 0.0000 | 0.0671 | 0.1220 | 1.2564 |